PMDA Review Report: ARCT-154 (Japan, 2023)

Government Record · Pharmaceuticals and Medical Devices Agency · November 22, 2023

Japan's drug regulator's review of ARCT-154, the first approved self-amplifying (replicon) RNA vaccine.

本剤は、レプリコン RNA（自己増殖型 RNA）を有効成分とする新有効成分含有医薬品である。

1
Official source

Japan's drug regulator's review of ARCT-154, the first approved self-amplifying (replicon) RNA vaccine.

Election Day is Tuesday, Nov 3. Know who you're voting for: your values vs. their record, with sources.Build my Vote Card →